At an 'in­flec­tion point': Gen­tiBio reels in $157M ahead of what CEO Adel Na­da sees as a Treg boom

Gen­tiBio CEO Adel Na­da says reg­u­la­to­ry T cells (or Tregs) are now where CAR-Ts were at the be­gin­ning of the last decade — at an in­flec­tion point. With a hand­ful of drug­mak­ers ze­ro­ing in on the pro­tec­tive class of im­mune cells, Na­da says big de­vel­op­ments are com­ing. And the proof, he says, is in his com­pa­ny’s lat­est megaround.

Na­da un­veiled a $157 mil­lion Se­ries A round on Wednes­day morn­ing from some big-name back­ers like the No­var­tis Ven­ture Fund and RA Cap­i­tal Man­age­ment. With a raise like that, it’s hard to imag­ine that a pub­lic de­but is too far down the road for Gen­tiBio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER